Stock market today: Stocks fall as investors rotate out of tech into Jackson Hole
In a turbulent market environment, Xencor Inc (NASDAQ: NASDAQ:XNCR) has experienced significant pressure, with its shares reaching a 52-week low of $15.27. According to InvestingPro data, technical indicators suggest the stock is in oversold territory, with a current ratio of 6.23 indicating strong liquidity. The biopharmaceutical company, known for its innovative approach to the discovery and development of engineered monoclonal antibodies, has seen its stock price struggle over the past year, culminating in this new low point. The decline reflects a broader trend in the biotech sector, which has faced investor skepticism amidst regulatory hurdles and a challenging economic climate. InvestingPro analysis reveals the company maintains a strong balance sheet with more cash than debt, though analysts anticipate sales decline in the current year. Over the past year, Xencor’s stock has undergone a substantial decrease, with a 1-year change showing a decline of -36.94%, underscoring the difficulties faced by the company in maintaining its market value amidst a competitive and uncertain landscape. For deeper insights into Xencor’s valuation and growth prospects, InvestingPro subscribers can access 12 additional expert tips and comprehensive financial analysis in the Pro Research Report.
In other recent news, Xencor Inc. announced it will restate its financial statements for the fiscal year ending December 31, 2023, and subsequent quarters through September 30, 2024, due to identified accounting errors. These errors include misclassification of a royalty transaction with OMERS Life Sciences, leading to understated accounts receivable by $12.4 million and overstated deferred income by $156.9 million. The company also found misstatements in research and development expenses, resulting in an uncertain tax position estimated at $5.6 million. Despite these financial restatements, Xencor stated that its cash, cash equivalents, and marketable debt securities remain unaffected.
In a separate development, Piper Sandler upgraded Xencor’s stock from Neutral to Overweight, with a new price target of $30.00, citing the company’s expanding pipeline and upcoming clinical data. Xencor plans to release initial Phase I data for XmAb942 in the first half of 2025 and initiate several other studies, including a Phase Ib/IIa study of plamatomab in rheumatoid arthritis. The company also has multiple key developments anticipated for 2025, including Phase II data for vudalimab in prostate cancer and lung cancer studies. Additionally, Xencor reported a cash reserve of $754 million as of the third quarter of 2024, expected to support its operations until 2028.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.